Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma
Lung cancer is among the most common malignant diseases in Russia. In 80–90%, its morphological type is nonsmall cell lung cancer. Stage IV primary advanced lung cancer is diagnosed in 41% of patients. Median overall survival in stage IV patients receiving chemotherapy is 7–12 months. Treatment for...
Saved in:
| Main Authors: | L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, P. N. Meshcheryakov, S. V. Oskin, S. N. Kabanov, N. Yu. Samaneva, Ya. V. Svetitskaya, A. V. Tishina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ANO "Perspective of oncology"
2021-03-01
|
| Series: | Южно-Российский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.cancersp.com/jour/article/view/105 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE)
by: L. Yu. Vladimirova, et al.
Published: (2016-04-01) -
Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
by: Avinash Vijaykumar Pandey, et al.
Published: (2015-01-01) -
Bevacizumab in maintenance therapy for ovarian cancer patients
by: L. Yu. Vladimirova, et al.
Published: (2020-08-01) -
A rare presentation of the diffuse dermal mucinosis in adenocarcinoma of the lungs treated with pembrolizumab and pemetrexed
by: Karen Koch, MBChB (UCT), FCDerm (SA), FRACP, MMed (Derm), et al.
Published: (2025-07-01) -
Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
by: Andy Liu, et al.
Published: (2023-09-01)